The Hikma Pharmaceuticals Board is recommending a final dividend of 30 cents per share (approximately 23 pence per share) (2018: 26 cents per share) bringing the total dividend for the full year to 44 cents per share (approximately 34 pence per share) (2018: 38 cents per share). The proposed dividend will be paid on 7 May 2020 to eligible shareholders on the register at the close of business on 20 March 2020, subject to approval at the Annual General Meeting on 30 April 2020.
Other financial highlights include:
Group revenue of $2,207 million, up 7%
Group operating profit of $493 million, up 33%
Basic earnings per share of 200.8 cents, up 72%
Cashflow from operating activities of $472 million, up 10%
Net debt reduced to $242 million and low leverage maintained (net debt to core EBITDA2 ratio 0.4x)